MedPath

Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study

Not Applicable
Completed
Conditions
Sports Nutritional Sciences
Interventions
Other: [11C]diprenorphine
Registration Number
NCT02112695
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Abnormal opioid system have been identified in addictive behavior and activity of the opioid system has also shown a strong link with the nutritional balance. A significant increase in endorphin levels was noticed after exercise, proportional to the duration and intensity of this activity. One brain imaging study showed an increase in opioid activity in athletes after endurance training. However , a decrease in opioid tone related to receptor desensitization in the brain has been raised in the sport and it is possible to feel like , the subject must perform physical exercise more frequently . Consequently, in order to deepen the hypothesis of addiction in high-level sport , the brain opioid activity should be assessed pre- training compared to a group of sedentary control subjects .

Preliminary results of a previous study the investigators are conducting on anorexia nervosa (AN ) show abnormalities that appear to be involved in self addiction anorexia nervosa and the regulation of gonadal function. However, the relation of cause and effect between these anomalies and undernutrition remains to be determined . Given the addictive component in the endurance sport and the variability of the nutritional status of its practitioners , evaluation of brain activity in these subjects could provide additional answers.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
35
Inclusion Criteria

For High-level sportswomen :

  • 18-35-year-old
  • High-level sportswomen
  • BMI>19kg/m2
  • Absence of eating disorders
  • In pre-competition period
  • Signature of written consent

For controls :

  • 18-35-year-old
  • Sedentary normal weight women
  • BMI>19kg/m2
  • Normal nutritional markers
  • Absence of eating disorders or other psychiatric or organic diseases
Exclusion Criteria
  • Oral contraception
  • Heart failure
  • Neuroleptics, antiparkinson drugs, alpha-methyl-dopa, beta blockers, inhibitors of monoamine oxidase-A or MOA-B, tricyclic antidepressants, selective serotonin reuptake inhibitor, thyme-regulators (lithium), anticonvulsant drugs, codeine, morphine, drugs containing tramadol, dopaminergic drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sportswomen[11C]diprenorphine3 micrograms \[11C\]diprenorphine
control subjects[11C]diprenorphine3 micrgrams \[11C\]diprenorphine
Primary Outcome Measures
NameTimeMethod
[11C]diprenorphine binding potential2 weeks

Value of \[11C\]diprenorphin binding potential in predifined brains regions. \[11C\]diprenorphin BP will be evaluated by brain positron emission tomography and MRI exam

Secondary Outcome Measures
NameTimeMethod
correlation [11C]diprenorphine BP2 weeks

Correlation between \[11C\]Diprenorphine binding potential and LH response during GnRH test

Trial Locations

Locations (1)

Service d'Endocrinologie - CHU Saint-Etienne

🇫🇷

Saint-Etienne, France

© Copyright 2025. All Rights Reserved by MedPath